220 related articles for article (PubMed ID: 25861217)
21. Precision Oncology: Evolving Clinical Trials across Tumor Types.
Song IW; Vo HH; Chen YS; Baysal MA; Kahle M; Johnson A; Tsimberidou AM
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046628
[TBL] [Abstract][Full Text] [Related]
22. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
[TBL] [Abstract][Full Text] [Related]
24. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
25. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
26. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
27. Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience.
Barsan V; Paul M; Gorsi H; Malicki D; Elster J; Kuo DJ; Crawford J
Cureus; 2019 Dec; 11(12):e6281. PubMed ID: 31827999
[TBL] [Abstract][Full Text] [Related]
28. Perspectives on research activity in the USA on Cancer Precision Medicine.
Bando H; Takebe N
Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
[TBL] [Abstract][Full Text] [Related]
29. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy according to next generation sequencing-based panel sequencing.
Saito M; Momma T; Kono K
Fukushima J Med Sci; 2018 Apr; 64(1):9-14. PubMed ID: 29628467
[TBL] [Abstract][Full Text] [Related]
31. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
32. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
33. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
34. OCTANE: Oncology Clinical Trial Annotation Engine.
Zeng J; Shufean MA; Khotskaya Y; Yang D; Kahle M; Johnson A; Holla V; Sánchez N; Mills Shaw KR; Bernstam EV; Meric-Bernstam F
JCO Clin Cancer Inform; 2019 Jul; 3():1-11. PubMed ID: 31265323
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
36. Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital.
Cao W; Yan C; Wang H; Tang T; Wang H; Liu D
Oncol Lett; 2019 Jun; 17(6):5425-5434. PubMed ID: 31186761
[TBL] [Abstract][Full Text] [Related]
37. Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations.
Choi SH; Jung SH; Chung YJ
Genomics Inform; 2017 Dec; 15(4):136-141. PubMed ID: 29307139
[TBL] [Abstract][Full Text] [Related]
38. Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.
Paasinen-Sohns A; Koelzer VH; Frank A; Schafroth J; Gisler A; Sachs M; Graber A; Rothschild SI; Wicki A; Cathomas G; Mertz KD
Neoplasia; 2017 Mar; 19(3):196-206. PubMed ID: 28161563
[TBL] [Abstract][Full Text] [Related]
39. When should we order a next generation sequencing test in a patient with cancer?
Colomer R; Mondejar R; Romero-Laorden N; Alfranca A; Sanchez-Madrid F; Quintela-Fandino M
EClinicalMedicine; 2020 Aug; 25():100487. PubMed ID: 32775973
[TBL] [Abstract][Full Text] [Related]
40. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
